On the basis of results in rat, L-arabinose decreased total cholesterol (TC), triglycerides (TG), fasting glucose, systolic blood pressure, increased high-density lipoprotein cholesterol (HDLC), and enhanced the glucose tolerance. The primary purposes of the present study was to determine the effects of consumption L-arabinose on metabolic syndrome in humans.All volunteers received L-Arabinose by dissolving it in water. The volunteers didn’t change the diet habits and lifestyles during the whole experiment. The trial lasted for 6 months, and experimental indicators were assayed every two months, which including weight, waist circumference, blood pressure, TG, TC, HDLC, low-density lipoprotein cholesterol (LDLC), fasting plasma glucose, erum uric acid, serum creatinine (Scr), bloodurea nitrogen (BUN), alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Our results showed that the L-arabinose decreased waist circumference, TC, fasting glucose, serum uric acid, ALT and slightly increased HDLCand slightly decreased diastolic blood pressure after 6 months. A tendency for decreased waist circumference, TC, fasting glucose, serum uric acid, ALT after 2, 4 and 6 months of treatment with L-arabinose was observed. In addition, L-arabinose decreased TC, LDLC and body weight. No effects on Scr, BUN, AST. In conclusions, L-arabinosewould reduce most the metabolic syndrome risk factors(decreased circumference, TC, fasting glucose, and so on), and treat the metabolic syndrome as a whole.The present study would provides strong evidence that long-term received L-arabinose would be manage metabolic syndrome.
Eva K, Panagiota P, Gregory K, George C. Metabolic syndrome: definitions and controversies. BMC Med 2011; 9: 48-60. http://dx.doi.org/10.1186/1741-7015-9-48
Apridonidze T, Essah PA, Iuorno MJ, Nestler JE. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004; 90: 1929-35. http://dx.doi.org/10.1210/jc.2004-1045
McLaughlin T, Allison G, Abbasi F, Lamendola C, Reaven G. Prevalence of insulin resistance and associated cardiovascular disease risk factors among normal weight, overweight, and obese individuals. Metabolism 2004; 53: 495-9. http://dx.doi.org/10.1016/j.metabol.2003.10.032
Abhishek G, Vani G. Metabolic syndrome: What are the risks for humans. Biosci Trends 2010; 4(5): 204-12.
Diabetes Society of the Chinese Medical Association Metabolic Syndrome Study Group. Diabetes Society of the Chinese Medical Association on the recommendations of the metabolic syndrome. Chin J Diabetes 2004; 12(3): 156-200 (in chinese).
Cameron AJ, Shaw JE, Zimmet PZ. The metabolic syndrome: Prevalence in worldwide populations. Endocrinol Metab Clin North Am 2004; 33: 351-75. http://dx.doi.org/10.1016/j.ecl.2004.03.005
Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among U.S. adults. Diabetes Care 2004; 27: 2444-9. http://dx.doi.org/10.2337/diacare.27.10.2444
Bernhard S, Benjamin M. Fungal arabinan and L-arabinose metabolism. Appl Microbiol Biotechnol 2011; 89: 1665-73. http://dx.doi.org/10.1007/s00253-010-3071-8
Schutte JB, De-Jong J, Van-Weerden EJ, Tamminga S. Nutritional implications of L-arabinose in pigs. Br J Nutr 1992; 68: 195-207. http://dx.doi.org/10.1079/BJN19920077
Segal S, Foley JB. The metabolic fate of C14 labeled pentoses in man. J Clin Invest 1959; 38: 407-13. http://dx.doi.org/10.1172/JCI103815
Seri K, Sanai K, Matsuo N, Kawakubo K, Xue C, Inoue S. Larabinose selectively inhibits intestinal sucrase in an uncompetitive manner and suppresses glycemic response after sucrose ingestion in animals. Metabolism 1996; 45: 1368-74. http://dx.doi.org/10.1016/S0026-0495(96)90117-1
Inger KM, Ole H, Inge T, Jens JH, Jens RA, Klaus B. The effects of L-arabinose on intestinal sucrase activity: doseresponse studies in vitro and in humans. Am J Clin Nutr 2011; 94: 472-78. http://dx.doi.org/10.3945/ajcn.111.014225
Gilbert RK, Samuel CK, Patti LK, Robert BL, Nicholas VP, Harry GP. A combination of l-arabinose and chromiumlowers circulating glucose and insulin levels after an acute oral sucrose challenge. Nutr J 2011; 10: 42-7. http://dx.doi.org/10.1186/1475-2891-10-42
Osaki S, Kimura T, Sugimoto T, Hizukuri S, Iritani N. Larabinose feeding prevents increases due to dietary sucrose in lipogenic enzymes and triacylglycerol levels in rats. J Nutr 2001; 131(3): 796-9.
HE L, Man QQ, Qiu ZL, Fu P, Wang XG. Effects of LArabinose on Growth and Carbohydrate, Lipid Metabolism in Wistar Rats with Normal Feeding and High-Sucrose and High-Fat Feeding. Chinese Journal of Food Hygiene 2009; 21: 406-9 (in chinese).
Gilbert RK, Samuel CK, Patti LK, Robert BL, Nicholas VP, Harry GP. A combination of l-arabinose and chromium lowers circulating glucose and insulin levels after an acute oral sucrose challenge. Nutr J 2011; 10: 42-7. http://dx.doi.org/10.1186/1475-2891-10-42
Harry GP, Bobby E, Debasis B, Sidney S. Inhibition by Natural Dietary Substances of Gastrointestinal Absorption of Starch and Sucrose in Rats. Subchronic Studies. Int J Med Sci 2007; 4(4): 209-15.
Yu X, Yu-fang B, Min X, et al. Cross-sectional and longitudinal association of serum alanine aminotransaminase and c-glutamyltransferase with metabolic syndrome in middle-aged and elderly Chinese people. J Diabetes 2011; 3: 38-47. http://dx.doi.org/10.1111/j.1753-0407.2010.00111.x
Ju-Mi L, Hyeon CK, Hye MC, Sun MO, Dong PC, II S. Association Between Serum Uric Acid Level and Metabolic Syndrome. J Prev Med Public Health 2012; 45(3): 181-7. http://dx.doi.org/10.3961/jpmph.2012.45.3.181
Eiji O, Ryu K, Kenichi W, Vijayakumar S. Prevalence of Metabolic Syndrome Increases with the Increase in Blood Levels of Gamma Glutamyltransferase and Alanine Aminotransferase in Japanese Men and Women. Inter Med 2009; 48: 1343-50. http://dx.doi.org/10.2169/internalmedicine.48.2094
Ishizaka N, Ishizaka Y, Toda E, Nagai R, Yamakado M. Association between serum uric acid, metabolic syndrome, and carotid atherosclerosis in Japanese individuals. Arterioscler Thromb Vasc Biol 2005; 25(5): 1038-44. http://dx.doi.org/10.1161/01.ATV.0000161274.87407.26
Lin SD, Tsai DH, Hsu SR. Association between serum uric acid level and components of the metabolic syndrome. J Chin Med Assoc 2006; 69(11): 512-6. http://dx.doi.org/10.1016/S1726-4901(09)70320-X
Goessling W, Massaro JM, Vasan RS, D Agostino RB Sr, Ellison RC, Fox CS. Aminotransferase levels and 20-year risk of metabolic syndrome, diabetes, and cardiovascular disease. Gastroenterology 2008; 135(6): 1935-44. http://dx.doi.org/10.1053/j.gastro.2008.09.018
Wang JY, Chen YL, Hsu CH, Tang SH, Wu CZ, Pei D. Predictive value of serum uric Acid levels for the diagnosis of metabolic syndrome in adolescents. J Pediatr 2012; 161(4): 753-6. http://dx.doi.org/10.1016/j.jpeds.2012.03.036
Chiou WK, Huang DH, Wang MH, Lee YJ, Lin JD. Significance and association of serum uric acid (UA) levels with components of metabolic syndrome (MS) in the elderly. Arch Gerontol Geriatr 2012; 55(3): 724-8. http://dx.doi.org/10.1016/j.archger.2012.03.004
Kang DH. Potential role of uric Acid as a risk factor for cardiovascular disease. Korean J Intern Med 2010; 25(1): 18-20. http://dx.doi.org/10.3904/kjim.2010.25.1.18
Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med 2008; 359(17): 1811-21. http://dx.doi.org/10.1056/NEJMra0800885
Sautin YY, Nakagawa T, Zharikov S, Johnson RJ. Adverse effects of the classic antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative/nitrosative stress. Am J Physiol Cell Physiol 2007; 293(2): 584-96. http://dx.doi.org/10.1152/ajpcell.00600.2006
Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 2004; 114(12): 1752-61.
Marchesini G, Brizi M, Bianchi G, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001; 50(8): 1844-50. http://dx.doi.org/10.2337/diabetes.50.8.1844
Ignacio GV, Tahir K, Luis R. Espinoza. Efficacy and safety of febuxostat in patients with hyperuricemia and gout. Ther Adv Musculoskel Dis 2011; 3(5): 245-53. http://dx.doi.org/10.1177/1759720X11416405
Mark D, Harris, Lori B, Siegel, Jeffrey A, Alloway. Gout and Hyperuricemia. Am Fam Physician 1999; 59(4): 925-34.
Simon C, Earl SF. Why have total cholesterol levels declined in most developed countries. BMC Public Health 2011; 11: 641-5. http://dx.doi.org/10.1186/1471-2458-11-641
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285(19): 2486-97. http://dx.doi.org/10.1001/jama.285.19.2486
Michel DL. Commentary on the clinical management of metabolic syndrome: why a healthy lifestyle is important. BMC Med 2012; 10: 139-48. http://dx.doi.org/10.1186/1741-7015-10-139
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright (c) 2013 Ziming Yang, Dianpeng Li, Haiying Jiang, Guiyun Qian, Weiguo Sui, Guimian Zou , Hourui Zhang